Emerging issues in management of sexually transmitted diseases in HIV infection

Current Infectious Disease Reports

Volumn 9, Issue 6, 2007, Pages 518-530

  Hall, Christopher S ^b   Marrazzo, Jeanne D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; PENICILLIN G; PLACEBO; PROBENECID; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE; TINIDAZOLE; VALACICLOVIR;

ADD ON THERAPY; BACTERIAL INFECTION; CHLAMYDIASIS; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE COURSE; GONORRHEA; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOGRANULOMA VENEREUM; MEDICAL CARE; MUCOSA; NEUROSYPHILIS; REVIEW; RISK ASSESSMENT; SCREENING; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SKIN ULCER; SUPERINFECTION; SYPHILIS; TRICHOMONIASIS; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 36049016674     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-007-0077-1     Document Type: Review

References (97)

1. Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America: Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003, 52(RR-12):1-24. [Published erratum in MMWR Recomm Rep 2004, 53:744.]
2. STD Control Program and the HIV/AIDS Control Program, Public Health - Seattle and King County, Seattle, Washington, USA: Sexually transmitted disease and HIV screening guidelines for men who have sex with men. Sex Transm Dis 2001, 28:457-459.
3. Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1-94.
4. Lo TQ, Samuel MC, Kent C, et al.: Characteristics of MSM syphilis cases using the Internet to seek male sex partners, California, 2001-2003. Presented at the STD/HIV Prevention and the Internet Conference. Washington, DC; August 25-27, 2003.
5. Bull SS, Rietmeijer C, Fortenberry JD, et al.: Practice patterns for the elicitation of sexual history, education, and counseling among providers of STD services: results from the gonorrhea community action project (GCAP). Sex Transm Dis 1999, 26:584-589.
6. Duffus WA, Barragan M, Metsch L, et al.: Effect of physician specialty on counseling practices and medical referral patterns among physicians caring for disadvantaged human immunodeficiency virus-infected populations. Clin Infect Dis 2003, 36:1577-1584.
7. Elford J, Bolding G, Maguire M, Sherr L: Do gay men discuss HIV risk reduction with their GP? AIDS Care 2000, 12:287-290.
8. Morin SF, Koester KA, Steward WT, et al.: Missed opportunities: prevention with HIV-infected patients in clinical care settings. J Acquir Immune Defic Syndr 2004, 36:960-96
9. Thrun M, Burman WJ, Britt DE, Rietmeijer CA: Successful implementation of risk-reduction discussions in a primary care setting for those living with HIV. Presented at the National HIV Prevention Conference. Atlanta; July 27-30, 2003.
10. Centers for Disease Control and Prevention: Diagnoses of HIV/AIDS-32 States, 2000-2003. MMWR Morb Mortal Wkly Rep 2004, 53:1106-1110.
11. Erbelding EJ, Chung SE, Kamb ML, et al.: New sexually transmitted diseases in HIV-infected patients: markers for ongoing HIV transmission behavior. J Acquir Immune Defic Syndr 2003, 33:247-252.
12. Centers for Disease Control and Prevention (CDC): Trends in primary and secondary syphilis and HIV infections in men who have sex with men-San Francisco and Los Angeles, California, 1998-2002. MMWR Morb Mortal Wkly Rep 2004, 53:575-578.
13. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394. [Comment in: N Engl J Med 2002, 347:438-439; 1889-1890; author reply 1889-1890.]
14. Weinstock HS, Zaidi I, Heneine W, et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004, 189:2174-2180.
15. Golden MR, Wood RW, Buskin SE, et al.: Ongoing risk behavior among persons with HIV in medical care. AIDS Behav 2007, 11:726-735.
16. Fisher JD, Fisher WA, Bryan AD, Misovich SJ: Information-motivation-behavioral skills model-based HIV risk behavior change intervention for inner-city high school youth. Health Psychol 2002, 21:177-186.
17. Richardson JL, Milam J, McCutchan A, et al.: Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS 2004, 18:1179-1186.
18. Fleming DT, Wasserheit JN: From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999, 75:3-17.
19. Greenblatt RM, Lukehart SA, Plummer FA, et al.: Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 1988, 2:47-50.
20. Darrow WW, Echenberg DF, Jaffe HW, et al.: Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987, 77:479-483.
21. Stamm WE, Handsfield HH, Rompalo AM, et al.: The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 1988, 260:1429-1433.
22. Brown JM, Wald A, Hubbard A, et al.: Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 2007, 21:1515-1523.
23. LeGoff J, Weiss HA, Gresenguet G, et al.: Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007, 21:1569-1578.
24. Nagot N, Ouédraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790-799. [Comment in: N Engl J Med 2007,356:854-856; 2323-2324; author reply 2324.]
25. Truong HM, Kellogg T, Klausner JD, et al.: Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect 2006, 82:461-466.
26. Schwarcz S, Scheer S, McFarland W, et al.: Prevalence of HIV infection and predictors of high-transmission sexual risk behaviors among men who have sex with men. Am J Public Health 2007, 97:1067-1075.
27. Shoptaw S, Reback CJ: Methamphetamine use and infectious disease-related behaviors in men who have sex with men: implications for interventions. Addiction 2007, 102(Suppl 1):130-135.
28. Centers for Disease Control and Prevention (CDC): Primary and secondary syphilis - United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006, 55:269-273.
29. Centers for Disease Control and Prevention (CDC): Primary and secondary syphilis among men who have sex with men - New York City, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:853-856.
30. Kahn RH, Heffelfinger JD, Berman SM: Syphilis outbreaks among men who have sex with men: a public health trend of concern. Sex Transm Dis 2002, 29:285-287.
31. Ciesielski CA: Sexually transmitted diseases in men who have sex with men: an epidemiologic review. Curr Infect Dis Rep 2003, 5:145-152.
32. Golden MR, Marra CM, Holmes KK: Update on syphilis: resurgence of an old problem. JAMA 2003, 290:1510-1514.
33. Klausner JD, Wong W: Sexually transmitted diseases in men who have sex with men: a clinical review. Curr Infect Dis Rep 2003, 5:135-144.
34. Samuel MC, Lo T, Klausner J, et al.: Epidemic syphilis in California among gay and other men who have sex with men [abstract 550]. Presented at the International Society for Sexually Transmitted Diseases Research Congress. Ottawa, Canada; July 27-30, 2003.
35. Collis TK, Celum CL: The clinical manifestations and treatment of sexually transmitted diseases in human immunodeficiency virus-positive men. Clin Infect Dis 2001, 32:611-622.
36. Musher DM, Hamill RJ, Baughn RE: Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. Ann Intern Med 1990, 113:872-881.
37. Hutchinson CM, Hook EW 3rd, Shepherd M, et al.: Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med 1994, 121:94-100.
38. Rompalo AM, Joesoef MR, O'Donnell JA, et al.: Clinical manifestations of early syphilis by HIV status and gender: results of the syphilis and HIV study. Sex Transm Dis 2001, 28:158-165.
39. Zetola NM, Klausner JD: Syphilis and HIV infection: an update. Clin Infect Dis 2007, 44:1222-1228.
40. Rolfs RT, Joesoef MR, Hendershot EF, et al.: A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997, 337:307-314. [Comment in: N Engl J Med 1997, 337:1697-1698; author reply 1698.]
41. Hicks CB, Benson PM, Lupton GP, Tramont EC: Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus (HIV) with Kaposi sarcoma. A diagnostic dilemma. Ann Intern Med 1987, 107:492-495. [Erratum in: Ann Intern Med 1987,107-946; Comment in: Ann Intern Med 1991,114:521-522.]
42. Tikjob G, Russel M, Petersen CS, et al.: Seronegative secondary syphilis in a patient with AIDS: identification of Treponema pallidum in biopsy specimen. J Am Acad Dermatol 1991, 24:506-508.
43. Ghanem KG, Erbelding EJ, Cheng WW, Rompalo AM: Doxycycline compared with benzathine penicillin for the treatment of early syphilis. Clin Infect Dis 2006, 42: e45-49.
44. Lukehart SA, Godornes C, Molini BJ, et al.: Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004, 351:154-158.
45. Mitchell SJ, Engelman J, Kent CK, et al.: Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin Infect Dis 2006, 42:337-345.
46. Simon RP: Neurosyphilis. Arch Neurol 1985, 42:606-613.
47. Lukehart SA, Hook EW 3rd, Baker-Zander SA, et al.: Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988, 109:855-862.
48. Marra CM, Maxwell CL, Smith SL, et al.: Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004, 189:369-376.
49. Marra CM, Maxwell CL, Tantalo L, et al.: Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004, 38:1001-1006.
50. Ghanem KG, Rompalo AM, Moore RD, et al.: Neurosyphilis in a Clinical Cohort of HIV-Infected Patients. Presented at the International Society for Sexually Transmitted Diseases Research Congress. Seattle; July 29-August 1, 2007.
51. Flood JM, Weinstock HS, Guroy ME, et al.: Neurosyphilis during the AIDS epidemic, San Francisco, 1985-1992. J Infect Dis 1998, 177:931-940.
52. Centers for Disease Control and Prevention (CDC): Symptomatic early ncurosyphilis among HIV-positive men who have sex with men - four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep 2007, 56:625-628.
53. Balba GP, Kumar PN, James AN, et al.: Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med 2006, 119:448.e21-5.
54. Hollander H: Cerebrospinal fluid normalities and abnormalities in individuals infected with human immunodeficiency virus. J Infect Dis 1988, 158:855-858.
55. Knapp JS, Fox KK, Trees DL, Whittington WL: Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997, 3:33-39. [Erratum in: Emerg Infect Dis 1997, 3:584.]
56. Kassutto S, Sax PE: HIV and syphilis coinfection: trends and interactions. AIDS Clin Care 2003, 15:9-15.
57. Mohr JA, Griffiths W, Jackson R, et al.: Neurosyphilis and penicillin levels in cerebrospinal fluid. JAMA 1976, 236:2208-2209.
58. Marra CM, Boutin P, McArthur JC, et al.: A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin Infect Dis 2000, 30:540-544.
59. Rompalo AM, Cannon RO, Quinn TC, et al.: Association of biologic false-positive reactions for syphilis with human immunodeficiency virus infection. J Infect Dis 1992, 165:1124-1126.
60. Centers for Disease Control and Prevention (CDC): Trends in Reportable Sexually Transmitted Diseases in the United States, 2004: National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis. Available at http://www.cdc.gov/std/stats04/04pdf/trends2004.pdf. Accessed August 28, 2007.
61. Kent CK, Chaw JK, Wong W, et al.: Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005, 41:67-74.
62. Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
63. Centers for Disease Control and Prevention (CDC): Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007, 56:332-336.
64. Holmes KK, Sparling PF, Mardh PA: Sexually Transmitted Diseases, 3rd edn. New York: McGraw-Hill; 1998:1454.
65. Johnson RE, Newhall WJ, Papp JR, et al.: Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections--2002. MMWR Recomm Rep 2002, 51(RR-15):1-38; quiz CE1-4.
66. Centers for Disease Control and Prevention (CDC): Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men--United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004, 53:335-338.
67. Centers for Disease Control and Prevention (CDC): Oral alternatives to cefixime for the treatment of uncomplicated Neisseria gonorrhoeae urogenital infections. Available at http://www.cdc.gov/std/treatment/ cefixime.htm. Accessed August 28, 2007.
68. Centers for Disease Control and Prevention (CDC): Notice to Readers: Discontinuation of Spectinomycin. MMWR Morb Mortal Wkly Rep 2006, 55:370.
69. Hall CS, McElroy MD, Samuel MC, et al.: Single-dose, oral cefpodoxime proxetil is effective for treatment of uncomplicated urogenital and rectal gonorrhea. Presented at the International Society for Sexually Transmitted Diseases Research Congress. Seattle; July 29-August 1, 2007.
70. Peterman TA, Tian LH, Metcalf CA, et al.: High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 2006, 145:564-572.
71. Golden MR, Whittington WL, Handsfield HH, et al.: Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005, 352:676-685. [Comment in: N Engl J Med 2005, 352:720-721; 2026-2027, author reply 2026-2027.]
72. Centers for Disease Control and Prevention (CDC): Lymphogranuloma venereum among men who have sex with men--Netherlands, 2003-2004. MMWR Morb Mortal Wkly Rep 2004, 53:985-988.
73. Nieuwenhuis RF, Ossewaarde JM, Götz HM, et al.: Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar 12 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004, 39:996-1003.
74. Schachter J, Moncada J: Lymphogranuloma venereum: how to turn an endemic disease into an outbreak of a new disease? Start looking. Sex Transm Dis 2005, 32:331-332.
75. Benson CA, Kaplan JE, Masur H, et al.: Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004, 53(RR-15):1-112.
76. Xu F, Sternberg MR, Kottiri BJ, et al.: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296:964-973.
77. Wald A, Zeh J, Selke S, et al.: Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000, 342:844-850.
78. Schacker T, Zeh J, Hu HL, et al.: Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998, 178:1616-1622.
79. Strick LB, Wald A, Celum C: Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin Infect Dis 2006, 43:347-356.
80. Schacker T, Ryncarz AJ, Goddard J, et al.: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998, 280:61-66.
81. Schacker T, Zeh J, Hu H, et al.: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002, 186:1718-1725.
82. Guerry SL, Bauer HM, Klausner JD, et al.: Recommendations for the selective use of herpes simplex virus type 2 serological tests. Clin Infect Dis 2005, 40:38-45.
83. DeJesus E, Wald A, Warren T, et al.: Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:1009-1016. [Erratum in: J Infect Dis 2003, 188:1404.]
84. Cates W Jr: Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999, 26(4 Suppl):S2-7.
85. Centers for Disease Control and Prevention (CDC): Tracking Hidden Epidemics: Trends in STDs in the United States. Available at http://www.cdc.gov/NCHSTP/dstd/Stats_Trends/STD_Trends.pdf. Accessed August 28, 2007.
86. Centers for Disease Control and Prevention (CDC): Prevention of genital HPV Infection and sequelae: report of an external consultants' meeting. Available at http://www.cdc.gov/nchstp/dstd/ Reports_Publications/HPVSupplement%20.pdf. Accessed August 28, 2007.
87. Sobhani I, Vuagnat A, Walker F, et al.: Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 2001, 120:857-866. [Comment in: Gastroenterology 2001, 120:1046-1048.]
88. Da Costa MM, Hogeboom CJ, Holly EA, Palefsky JM: Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant. J Infect Dis 2002, 185:1229-1237.
89. Haga T, Kim SH, Jensen RH, et al.: Detection of genetic changes in anal intraepithelial neoplasia (AIN) of HIV-positive and HIV-negative men. J Acquir Immune Defic Syndr 2001, 26:256-262.
90. Holly EA, Ralston ML, Darragh TM, et al.: Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001, 93:843-849.
91. Palefsky JM, Holly EA, Ralston ML, et al.: Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001, 183:383-391.
92. Chin-Hong PV, Palefsky JM: Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002, 35:1127-1134.
93. Piketty C, Kazatchkine MD: Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Curr HIV/AIDS Rep 2005, 2:140-145.
94. Piketty C, Darragh TM, Da Costa M, et al.: High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003, 138:453-459.
95. Wilkin TJ, Palmer S, Brudney KF, et al.: Anal intraepithelial neoplasia in heterosexual and homosexual HIV-positive men with access to antiretroviral therapy. J Infect Dis 2004, 190:1685-1691.
96. Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005, 19:1407-1414.
97. Berry JM, Palefsky JM: Anogenital Neoplasia and HIV. HIV InSite Knowledge Base Chapter, November 1998. Available at http://hivinsite.ucsf.edu/InSite?page=kb-06-04-02. Accessed August 28, 2007.